Abivax soars on report of Eli Lilly meeting French officials over possible deal Dec 22, 2025 05:33AM
Lilly completes Adverum acquisition for $3.56 per share plus CVRs Dec 9, 2025 08:30AM
Adverum urges shareholders to tender shares in Lilly acquisition offer Dec 1, 2025 07:03AM
Adverum Biotechnologies terminates Durham lease early for $7.5 million Nov 21, 2025 04:05PM
H.C. Wainwright Downgrades Adverum Biotechnologies (ADVM) to Neutral Nov 17, 2025 06:15AM


Nov 17, 2025 05:51AM Mizuho on Adverum Biotechnologies (ADVM): 'Seeing Upside at Current Valuation'
Oct 28, 2025 08:46AM Adverum Biotechnologies (ADVM) PT Raised at RBC Capital To Reflect Proposed LLY Acquisition
Oct 27, 2025 03:53AM Chardan Capital Markets Downgrades Adverum Biotechnologies (ADVM) to Neutral
Oct 24, 2025 08:26AM Adverum Biotechnologies (ADVM) Halted, News Pending
Sep 24, 2025 06:38AM Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Sep 23, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
Jun 25, 2025 04:24PM Adverum Biotechnologies (ADVM) PT Lowered to $12 at Mizuho
May 14, 2025 06:36PM Adverum Biotechnologies (ADVM) Misses Q1 EPS by 225c
Apr 16, 2025 10:30AM Adverum Biotechnologies (ADVM) PT Lowered to $5 at RBC Capital, Reflecting Increased OpEx
Mar 4, 2025 05:45AM Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Mar 3, 2025 04:01PM Adverum Biotechnologies (ADVM) Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
Nov 22, 2024 02:11PM Adverum Biotechnologies (ADVM) PT Lowered to $16 at Mizuho
Nov 18, 2024 07:09AM Adverum Biotechnologies (ADVM) Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Nov 15, 2024 04:07PM Adverum Biotechnologies (ADVM) Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Nov 5, 2024 08:06AM H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
Nov 5, 2024 06:57AM Adverum Biotechnologies (ADVM) PT Lowered to $10 at RBC Capital
Nov 4, 2024 07:31PM Adverum Biotechnologies (ADVM) Misses Q3 EPS by 130c
Oct 16, 2024 04:04PM Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Oct 16, 2024 08:00AM Adverum Biotechnologies (ADVM) Appoints Jason L. Mitchell as Chief Commercial Officer
Oct 14, 2024 07:55AM Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Oct 3, 2024 09:21AM Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Oct 3, 2024 06:41AM Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Sep 20, 2024 06:46AM Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Aug 19, 2024 09:24AM Adverum Biotechnologies (ADVM) PT Lowered to $20 at Mizuho
Aug 13, 2024 04:47PM Adverum Biotechnologies (ADVM) PT Lowered to $40 at Truist Securities
Aug 13, 2024 09:28AM TD Cowen Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
Aug 13, 2024 06:54AM Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Aug 13, 2024 06:11AM H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
Aug 12, 2024 05:14PM Adverum Biotechnologies (ADVM) Misses Q2 EPS by 89c
Aug 1, 2024 08:01AM Adverum Biotechnologies (ADVM) Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
Jul 17, 2024 12:00PM TD Cowen Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
Jun 25, 2024 06:04AM Oppenheimer Starts Adverum Biotechnologies (ADVM) at Outperform
Jun 11, 2024 08:02AM Adverum Biotechnologies (ADVM) Appoints Rabia Gurses Ozden as Chief Medical Officer